Microbot Medical (MBOT) Expected to Announce Earnings on Wednesday

Microbot Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Microbot Medical is expected to report Q3 2026 results on November 11, with analysts forecasting a loss of $0.08 per share and revenue of $0.01 million; a conference call is scheduled for November 13.
  • In its previous quarter, the company reported a loss of $0.08 per share, in line with estimates, and revenue of $0.24 million versus the $0.13 million consensus.
  • Analyst views are mixed, but MarketBeat lists an overall “Moderate Buy” rating and an average price target of $5.08. Shares opened at $1.09, within a 12-month range of $0.93 to $2.85.
  • Five stocks to consider instead of Microbot Medical.

Microbot Medical (NASDAQ:MBOT - Get Free Report) is anticipated to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect Microbot Medical to post earnings of ($0.08) per share and revenue of $0.01 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, analysts expect Microbot Medical to post ($0.30) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

Microbot Medical Stock Up 4.8%

Shares of NASDAQ:MBOT opened at $1.09 on Wednesday. Microbot Medical has a 12 month low of $0.93 and a 12 month high of $2.85. The company has a 50-day moving average price of $1.23 and a 200 day moving average price of $1.84.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MBOT. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Microbot Medical in a research note on Wednesday, October 21st. Citigroup started coverage on Microbot Medical in a report on Friday, October 23rd. They set a "market outperform" rating on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a research report on Friday, October 2nd. Zacks Research lowered shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Microbot Medical from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 24th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $5.08.

Check Out Our Latest Stock Analysis on Microbot Medical

Microbot Medical Company Profile

(Get Free Report)

Microbot Medical Inc NASDAQ: MBOT is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians' exposure to radiation.

The company's primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.

See Also

Earnings History for Microbot Medical (NASDAQ:MBOT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Microbot Medical Right Now?

Before you consider Microbot Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.

While Microbot Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines